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Impact Objectives
• Enable pain free skin biopsy and blood collection 
• Utilise the microbiopsy device to provide rapid diagnosis of skin issues and blood testing, thus 
providing actionable diagnoses for faster treatment and recovery  
• Use the new technology to move biopsy sampling out of medical centres and into the field, thus 
helping those in remote geographical areas by offering patients rapid diagnosis and treatment of not 
only skin conditions, but also infectious diseases
Revolutionising microsampling
Professor Tarl Prow and Dr Li Lin are Australian researchers that have developed a microbiopsy 
device. This sampling technology will not only minimise the need for painful sampling procedures in 
the diagnosis of skin disease, but will also decrease time to actionable diagnoses for both skin and blood 
testing. This new clinical and pathology approach will improve patient outcomes
Your current research is focused on skin 
sampling using microdevices. Can you 
explain more about how they work?
Our microbiopsy technology consists 
of a microbiopsy device and a modified 
spring-loaded blood lancet applicator. 
When applied, the microneedle captures 
a tiny sample of blood and skin. This sub-
millimetre microbiopsy platform technology 
is less painful than a conventional blood 
lancet, so there is no need for local 
anaesthetics and has a safety profile similar 
to existing blood lancets. 
What are the advantages of microsampling 
over traditional harvesting techniques?
Conventional methods of obtaining skin 
specimens involve invasive surgical 
techniques such as shave biopsy or Mohs 
surgery that require local anaesthetic 
injection, sutures and most result in 
scaring. Microsampling is quick and 
painless, which means physicians can 
sample many more areas than conventional 
biopsy approaches and repeat sampling 
over time. Conventional biopsy specimens 
are then preserved with formalin to 
maintain structural organisation and 
sent for histopathological analysis. 
Histopathological sections are rarely used 
for molecular fingerprinting in dermatology. 
Microsampling using our microbiopsy 
platform not only provides samples that 
are of higher quality than formalin fixed 
histopathological samples, but also have 
the capacity to target specific areas within 
a lesion. For blood sampling, patients have 
to undergo a phlebotomy procedure which 
requires a special room, trained healthcare 
workers, is painful and there are issues with 
needle stick injuries. Microsampling for 
blood removes all such barriers and risks.
Can you explain a little about absorbent 
microbiopsy techniques?
The absorbent microbiopsy is a simple 
approach where the microneedle that 
pierces the skin has an absorbent matrix. 
This device then captures a small amount of 
peripheral blood and lysed skin cell material 
within a porous matrix that will offer all the 
advantages that dried blood spot sampling 
is recognised for, but in miniature. This 
overcomes some issues associated with 
conventional blood spotting techniques. 
The blood sample can be dried or placed 
in buffer for single-step integration with 
molecular diagnostic kits. Current standard 
of care for blood testing involves collection 
of 20-60ml of blood using hypodermic 
needles and blood evacuation tubes, but 
only a tiny amount is needed for some tests. 
We believe that by combining the benefits 
of dried blood spotting and microneedles, 
defined quantities of blood can be extracted 
from the skin in a safe, painless and cost-
effective manner that is biologically stable. 
This can then be used for blood tests that 
are sensitive and the technologies can be 
tailored for low resource regions.
How will this technology benefit other  
areas of dermatology research?
Surprisingly, one of the areas that is 
benefiting is the cosmetics field. Their only 
options have been cell culture research, non-
invasive analysis and volunteers undergoing 
conventional biopsies. Now they are 
testing cosmetics in volunteers and taking 
microbiopsies to evaluate molecular changes 
in the treated skin. It is a very powerful tool 
for cosmeceutical development and testing. 
We are now working with groups around 
the globe who each have their own areas of 
investigative dermatology where microbiopsy 
is playing a large role. In Munich in Germany, 
we are working with a researchers learning 
about infant inflammatory disease; in Israel 
collaborators are using microbiopsy samples 
to detect leishmania in volunteers from 
Ghana and Ethiopia; in Brazil collaborators 
are applying microbiopsies to dogs to find 
signs of parasitic infection; and in New York, 
our collaborators are using microbiopsies 
to examine the molecular landscape of 
suspicious nevi in patients at risk for 
melanoma. Together we have done over 
2200 microbiopsies on many different body 
sites including the face and neck. There are 
many uses for this technology that we never 
imagined. We look forward to seeing how 
we can help these creative people put our 
technology to work.
Professor Tarl Prow Dr Li Lin
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Novel microbiopsy tools for 
minimum invasive sampling
The increase in incidents of skin disorders are leading to a corresponding increase in biopsies to extract 
sufficient material for analysis and diagnosis. Exciting new research into sub-millimetre extraction tools 
is helping to remove the need for painful and invasive extraction techniques
Human skin is the largest organ of the 
integumentary system, comprising up to 
seven layers of ectodermal tissue, offering 
protection for the underlying muscles, 
bones, ligaments and internal organs. While 
similar to the skin of many other mammals, 
it has much lower hair follicle density, and 
generally exhibits a fine hair rather than the 
thick coats that some animals have. This 
can lead to problems with skin conditions 
and overexposure to the sun’s rays and the 
complications that go with it. While the 
exposed parts of some mammals suffer 
from serious skin complaints, the relatively 
unprotected skin of humans is prone 
to a far greater incidence of lesions and 
potentially carcinogenic problems. Typically, 
an excisional biopsy is carried out when 
a melanoma is suspected or it is decided 
to remove a small tumour entirely for 
histopathological examination. A skin biopsy 
typically takes about 15 minutes, including 
preparation time, dressing the wound and 
detailed instructions for at-home care.
SAMPLING ISSUES
Biopsies of suspect areas are now a 
routine process, but remain one that is  
uncomfortable, risky and difficult to carry 
out in non-medical facilities. The collection 
of samples from the field is also of growing 
importance, but to do so with the current 
methods would be problematic. This has 
led to an interest in micro-dermatological 
sampling devices that are essentially non-
invasive and allow sampling under difficult 
or extreme conditions.
Traditional skin biopsies can involve 
harvesting a section of skin using either 
a sharp-edged tool such as a razor blade 
or a circular punch, which can vary in 
size from around 1.5mm up to 8mm in 
diameter, depending on the size of the 
sample required. Both methods usually 
result in some bleeding and may require 
a stitch to close them. Local anesthetic 
may be required and pain relief is often 
administered post procedure. Following 
the healing process, there is likely to be  
a scar and that can become a major issue 
if several biopsies are required. Healing 
can take several weeks and the results 
can be unsightly. The other option is to 
investigate a means of obtaining smaller, 
less invasive samples that don’t have 
such added complications, and that is the 
focus of the work of Professor Tarl Prow, 
Dr Li Lin and their team from The Future 
Industries Institute, University of South 
Australia and Dermatology Research Centre, 
The University of Queensland, Australia. 
Prow explains: ‘We believe microbiopsy 
technology will be most useful to the public 
in the form of an inexpensive device sold at 
pharmacies and in general practice clinics 
for blood testing and skin disease testing. 
The device is targeted at those with many 
lesions, longitudinal testing, cosmetically 
sensitive areas and children.’ 
HARVESTING SMALL SAMPLES
The major issue with current biopsy 
techniques is the sheer size of the sampling 
tool. These large cutting devices are 
intended to harvest a substantial amount 
of the area under investigation in order to 
give a reasonable indication of the lesion’s 
make-up. Prow and Lin’s team however, 
consider that harvesting smaller amounts 
from specific areas may actually increase the 
accuracy of the result, remove the need for 
pre-procedure anesthetic, and avoid scarring. 
Furthermore, sampling of this nature could 
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With the microsampling 
process now well-defined 
and proven, its use is likely 
to become increasingly 
widespread, not only in 
the field of skin disorders, 
but in an increasing 
number of medical 
applications too
take biopsies out of the medical centre and 
allow routine sample gathering in the field.
Microsampling is carried out using a 
specially made lancet, laser-etched from 
surgical-grade stainless steel. The cutting 
head of the device is typically just 0.5mm 
wide and 0.15mm thick, making it pin-prick 
sized. Crucially, however, the actual cutting 
tip consists of an accurately formed twin-
prong fork rather than a single point, and 
this allows a small sample of skin to be 
completely removed rather than just a cut 
made in the skin. The tiny piece of skin is 
sufficient to allow a physician to examine 
a specific skin complaint, but because 
it is possible to take a sample without 
substantial damage to the area, several 
samples can be harvested from specific 
areas, pinpointing any potential difference 
in the lesion or melanoma over its span.   
SMALLER SAMPLES, BETTER RESULTS
While small, the samples can be used to 
determine the molecular fingerprint – such 
as genotyping and RNA sequencing – of the 
skin sample, providing accurate analysis. 
The practice offers the distinct advantage of 
targeting specific areas of a skin lesion and 
can therefore provide exacting results for 
different regions of the sample area. This is 
generally not the case with large traditional 
extractions. That approach can lead to the 
gathering of material, which may be key 
to determining if a sun spot is likely to 
become skin cancer with a simple and non-
invasive technique.
Because microsampling can be carried out 
with relative ease, and leaves no lasting scar, 
it can be routinely used on patients who are at 
a higher risk of developing skin cancer before 
mutation has occurred, leading to a greater 
incidence of preventive medicine rather than 
playing catch-up with a tumour that has 
already taken hold. Furthermore, the micro-
sampled site is generally so small that it is not 
evident when healed, even multiple gathering 
can be taken from cosmetically sensitive areas, 
as well as those sites that could be associated 
with poor healing, without fear of leaving 
permanent damage or unsightly scaring.
BEYOND SKIN CANCER
With the process proven, Prow and Lin have 
been keen to examine other areas of medical 
procedure where it may also be advantageous. 
One of the most obvious is that of dried blood 
spot sampling, used routinely for the mass 
screening of serious and infectious diseases 
in the rural areas of poor and Third World 
countries. Current practice calls for up to 
60ml of blood to be taken from each subject, 
but a modified microsampling head with an 
inbuilt wick is capable of taking sufficient 
blood for analysis without needing to drain 
usual amounts via hypodermic needles. This 
has enormous benefits, not least the trauma 
that can be caused to younger patients, 
but also eliminates the need for a cold-
chain to transport the blood samples to the 
analytical laboratory.
While microsampling was developed as a 
more efficient means of gathering material 
for the identification of skin complaints and 
the potential for dysplastic nevi to develop 
further, the sampling tools have also been 
taken up and employed by other groups of 
researchers for a variety of different methods. 
An Israeli team is using these microsampling 
tools and the process to determine instances 
of leishmania amongst volunteers from 
countries prone to the Sandfly disease.
THE FUTURE OF MICROSAMPLING
With the microsampling process now well-
defined and proven, its use is likely to become 
increasingly widespread, not only in the 
field of skin disorders, but in an increasing 
number of medical applications too. The 
manufacturing processes for the micro-
samplers are well-defined, and production of 
these and variations of the harvesting prongs 
are now routine, making samples easy to 
harvest and analyse.
Microsampling is quick, clean, painless and 
non-invasive, making it the process of choice. 
The current method of skin punches and the 
need for anaesthetic and post-procedure care 
are being rendered obsolete, and that will 
bring harvesting out of the medical centre 
and into the field, where it has the potential to 
make some real differences in many areas of 
early diagnosis.
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